An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Baxalta; Momenta Pharmaceuticals
- 19 Apr 2017 Status changed from active, no longer recruiting to completed.
- 09 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Mar 2017.
- 09 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.